<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660760</url>
  </required_header>
  <id_info>
    <org_study_id>ACCRU-GI-1810</org_study_id>
    <secondary_id>NCI-2020-11436</secondary_id>
    <secondary_id>ACCRU-GI-1810</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT04660760</nct_id>
  </id_info>
  <brief_title>Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer</brief_title>
  <official_title>Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Academic and Community Cancer Research United</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of the combination of ramucirumab and&#xD;
      trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or&#xD;
      gastroesophageal junction cancer that has spread to other places in the body (advanced).&#xD;
      Ramucirumab may damage tumor cells by targeting new blood vessel formation.&#xD;
      Trifluridine/tipiracil is a chemotherapy pill and that may damage tumor cells by damaging&#xD;
      their deoxyribonucleic acid (DNA). Paclitaxel may block cell growth by stopping cell division&#xD;
      which may kill tumor cells. Giving ramucirumab and trifluridine/tipiracil will not be worse&#xD;
      than ramucirumab and paclitaxel in treating gastric or gastroesophageal junction cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To compare, in a non-inferiority fashion, the progression-free survival (PFS) in patients&#xD;
      with metastatic refractory gastric/gastroesophageal junction (GEJ) adenocarcinoma receiving&#xD;
      the combination of ramucirumab with trifluridine and tipiracil hydrochloride (TAS-102) versus&#xD;
      (vs.) paclitaxel and ramucirumab.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess overall survival (OS) in this patient population for each regimen. II. Assess&#xD;
      changes in patient quality of life (QOL) as measured by the linear analogue self-assessment&#xD;
      (LASA) questionnaire for each regimen.&#xD;
&#xD;
      III. To determine the safety of the combination of ramucirumab with TAS-102 in this patient&#xD;
      population.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM A: Patients receive TAS-102 orally (PO) twice daily (BID) on days 1-5 and 8-12, and&#xD;
      ramucirumab intravenously (IV) over 30-60 minutes on days 1 and 15. Treatment repeats every&#xD;
      28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15, and ramucirumab&#xD;
      IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30-35 days, then every 3&#xD;
      months for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Progression free survival is defined as the time interval between randomization date and the date of disease progression or death (referred to as an &quot;event&quot;), whichever occurs first. Disease progression will be determined based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. The median progression free survival will be estimated using the Kaplan-Meier method for each arm, corresponding 95% confidence intervals, and hazard ratio comparing the treatment arm to the control arm will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Median OS will be estimated using the Kaplan-Meier method. Patients who do not experience death while on study will be censored at the last known date alive. The median OS and corresponding 95% confidence interval will be reported by arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Patient reported QOL outcomes will be collected using the Linear Analog Self-Assessment (LASA) Questionnaire. Data will be collected each cycle. Mean values of the first question (regarding overall QOL) at each cycle will be plotted, and stratified by arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Adverse events will be recorded using Common Terminology Criteria for Adverse Events version 5.0. The proportion of patients who experience a grade 3+ adverse event at least possibly related to treatment will be reported by arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Clinical Stage III Gastric Cancer AJCC v8</condition>
  <condition>Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Clinical Stage IV Gastric Cancer AJCC v8</condition>
  <condition>Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Clinical Stage IVA Gastric Cancer AJCC v8</condition>
  <condition>Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Clinical Stage IVB Gastric Cancer AJCC v8</condition>
  <condition>Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Locally Advanced Unresectable Gastric Adenocarcinoma</condition>
  <condition>Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Metastatic Gastric Adenocarcinoma</condition>
  <condition>Metastatic Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Pathologic Stage III Gastric Cancer AJCC v8</condition>
  <condition>Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IIIA Gastric Cancer AJCC v8</condition>
  <condition>Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IIIB Gastric Cancer AJCC v8</condition>
  <condition>Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IIIC Gastric Cancer AJCC v8</condition>
  <condition>Pathologic Stage IV Gastric Cancer AJCC v8</condition>
  <condition>Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm A (TAS-102, ramucirumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive TAS-102 PO BID on days 1-5 and 8-12, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (paclitaxel, ramucirumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (paclitaxel, ramucirumab)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Arm A (TAS-102, ramucirumab)</arm_group_label>
    <arm_group_label>Arm B (paclitaxel, ramucirumab)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (TAS-102, ramucirumab)</arm_group_label>
    <arm_group_label>Arm B (paclitaxel, ramucirumab)</arm_group_label>
    <other_name>Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B</other_name>
    <other_name>Cyramza</other_name>
    <other_name>IMC-1121B</other_name>
    <other_name>LY3009806</other_name>
    <other_name>Monoclonal Antibody HGS-ETR2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine and Tipiracil Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (TAS-102, ramucirumab)</arm_group_label>
    <other_name>Lonsurf</other_name>
    <other_name>TAS 102</other_name>
    <other_name>TAS-102</other_name>
    <other_name>Tipiracil Hydrochloride Mixture with Trifluridine</other_name>
    <other_name>Trifluridine/Tipiracil</other_name>
    <other_name>Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Histological or cytological confirmation of adenocarcinoma of the stomach or&#xD;
             gastroesophageal junction&#xD;
&#xD;
          -  Have locally advanced unresectable or metastatic disease that has progressed =&lt; 180&#xD;
             days since last treatment&#xD;
&#xD;
          -  One or more measurable or nonmeasurable evaluable lesions per Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST)&#xD;
&#xD;
          -  Planned for second line treatment defined by failing or were intolerant to previous&#xD;
             standard chemotherapies containing one or more of the following agents:&#xD;
&#xD;
               -  Fluoropyrimidine (IV 5-FU or capecitabine) and platinum (cisplatin or&#xD;
                  oxaliplatin)&#xD;
&#xD;
               -  Trastuzumab in case of HER2-positive disease&#xD;
&#xD;
               -  NOTE: For the patients whose disease recurred =&lt; 168 days from the last dose of&#xD;
                  adjuvant anticancer chemotherapy, that adjuvant anticancer chemotherapy is&#xD;
                  counted as 1 prior chemotherapy line&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1&#xD;
&#xD;
          -  Ability to swallow oral medications&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3 (obtained =&lt; 7 days prior to&#xD;
             registration)&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3 (obtained =&lt; 7 days prior to registration)&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL (obtained =&lt; 7 days prior to registration)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) (obtained =&lt; 7 days prior to&#xD;
             registration)&#xD;
&#xD;
          -  Aspartate transaminase (AST) and alanine transaminase (ALT) =&lt; 3 x ULN ( =&lt; 5.0 x UNL,&#xD;
             if with liver metastasis) (obtained =&lt; 7 days prior to registration)&#xD;
&#xD;
          -  International normalized ratio (INR) =&lt; 1.5 x ULN, and a partial thromboplastin time&#xD;
             (PTT) =&lt; 5 seconds above the ULN (unless receiving anticoagulation therapy) (obtained&#xD;
             =&lt; 7 days prior to registration)&#xD;
&#xD;
               -  Note: Patients receiving warfarin must be switched to low molecular weight&#xD;
                  heparin and have achieved stable coagulation profile prior to first dose of&#xD;
                  protocol therapy&#xD;
&#xD;
               -  Note: Patients on full-dose anticoagulation must be on a stable dose (minimum&#xD;
                  duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH)&#xD;
&#xD;
               -  Exception: If receiving warfarin, the patient must have an INR =&lt; 3.0. For&#xD;
                  heparin and LMWH there should be no active bleeding (that is, no bleeding within&#xD;
                  14 days prior to first dose of protocol therapy) or pathological condition&#xD;
                  present that carries a high risk of bleeding (for example, tumor involving major&#xD;
                  vessels or known varices)&#xD;
&#xD;
          -  Urinary protein is =&lt; 1+ on dipstick or routine urinalysis (UA; if urine dipstick or&#xD;
             routine analysis is &gt;= 2+, a 24-hour urine collection for protein must demonstrate =&lt;&#xD;
             1000 mg of protein in 24 hours to allow participation in this protocol) (obtained =&lt; 7&#xD;
             days prior to registration)&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 times the ULN or creatinine clearance (measured via 24-hour urine&#xD;
             collection) &gt;= 50 mL/minute (that is, if serum creatinine is &gt;= 1.5 times the ULN, a&#xD;
             24-hour urine collection to calculate creatinine clearance must be performed)&#xD;
             (obtained =&lt; 7 days prior to registration)&#xD;
&#xD;
          -  Negative pregnancy test done =&lt; 7 days prior to registration, for women of&#xD;
             childbearing potential only&#xD;
&#xD;
          -  Ability to complete questionnaire(s) by themselves or with assistance&#xD;
&#xD;
          -  Provide informed written consent =&lt; 28 days prior to registration&#xD;
&#xD;
          -  Willing to return to enrolling institution for follow-up (during the Active Monitoring&#xD;
             Phase of the study)&#xD;
&#xD;
          -  Because the teratogenicity of ramucirumab is not known, the patient, if sexually&#xD;
             active, must be postmenopausal, surgically sterile, or using effective contraception&#xD;
             (hormonal or barrier methods)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following because this study involves an investigational agent whose&#xD;
             genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are&#xD;
             unknown:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and toxicity of the&#xD;
             prescribed regimens&#xD;
&#xD;
          -  Previous treatment with TAS-102 or ramucirumab&#xD;
&#xD;
          -  Previous taxane therapy =&lt; 180 days prior to registration&#xD;
&#xD;
          -  Any grade 3-4 gastrointestinal (GI) bleeding =&lt; 90 days prior to registration&#xD;
&#xD;
          -  History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other&#xD;
             significant thromboembolism (venous port or catheter thrombosis or superficial venous&#xD;
             thrombosis are not considered &quot;significant&quot;) =&lt; 90 days prior to registration&#xD;
&#xD;
          -  Any arterial thromboembolic events, including but not limited to myocardial&#xD;
             infarction, transient ischemic attack, cerebrovascular accident, or unstable angina,&#xD;
             =&lt; 180 days prior to registration&#xD;
&#xD;
          -  Prior history of GI perforation/fistula =&lt; 180 days of registration or risk factors&#xD;
             for perforation&#xD;
&#xD;
          -  Serious or nonhealing wound, ulcer, or bone fracture =&lt; 28 days prior to registration&#xD;
&#xD;
          -  Major surgery =&lt; 28 days prior to first dose of protocol therapy, or minor&#xD;
             surgery/subcutaneous venous access device placement =&lt; 7 days prior to registration&#xD;
&#xD;
          -  Elective or planned major surgery to be performed during the course of the clinical&#xD;
             trial&#xD;
&#xD;
          -  Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a&#xD;
             history of hepatic encephalopathy or clinically meaningful ascites resulting from&#xD;
             cirrhosis. NOTE: Clinically meaningful ascites is defined as ascites from cirrhosis&#xD;
             requiring diuretics or paracentesis&#xD;
&#xD;
          -  Uncontrolled or poorly-controlled hypertension (&gt;= 150 mmHg systolic or &gt;= 90 mmHg&#xD;
             diastolic for &gt;= 4 weeks) despite standard medical management&#xD;
&#xD;
          -  Immunocompromised and known to be human immunodeficiency virus (HIV) positive and&#xD;
             currently receiving antiretroviral therapy&#xD;
&#xD;
               -  NOTE: Patients known to be HIV positive, but without clinical evidence of an&#xD;
                  immunocompromised state, are eligible for this trial&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Receiving any other investigational agent which would be considered as a treatment for&#xD;
             the primary neoplasm&#xD;
&#xD;
          -  Other active malignancy =&lt; 3 years prior to registration. EXCEPTIONS: Non-melanotic&#xD;
             skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior&#xD;
             malignancy, they must not be receiving other specific treatment for their cancer&#xD;
&#xD;
          -  Receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or&#xD;
             similar agents. NOTE: Once-daily aspirin use (maximum dose 325 mg/day) is permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad B Sonbol</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic and Community Cancer Research United</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7448</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamad B. Sonbol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveen Khan</last_name>
      <phone>323-865-0524</phone>
      <email>Naveen.khan@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Syma Iqbal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RPS Intake Inbox</last_name>
      <email>FLARPSINTAKE@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Starr, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic-Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7448</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Arun Nagarajan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center NCI Community Oncology Research Program</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7448</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kendrith M. Rowland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7448</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Pashtoon M. Kasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7448</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Shaker R. Dakhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Minnesota Community Oncology Research Consortium</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7448</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel M. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7448</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kelsey A. Klute</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital Cancer Center Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Mohoney</last_name>
      <phone>920-433-8889</phone>
      <email>Stuart.Mohoney@hshs.org</email>
    </contact>
    <investigator>
      <last_name>Anthony J. Jaslowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Milwaukee West</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operation</last_name>
      <phone>507-538-7448</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Federico A. Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lexatumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

